![]() |
市場調查報告書
商品編碼
1827773
2025年全球預填充式注射器市場報告Pre Filled Syringes Global Market Report 2025 |
近年來,預填充式注射器市場快速擴張,市場規模從2024年的83億美元成長至2025年的93.9億美元,複合年成長率為13.1%。預測期內的成長歸因於製藥和生物技術行業的成長、生技藥品和疫苗的擴張、對方便用戶使用且精準給藥的需求、家庭醫療保健和自我給藥的興起,以及藥品安全和包裝監管標準的提高。
預計未來幾年預填充式注射器市場將快速成長,到2029年將達到160.9億美元,年複合成長率(CAGR)為14.4%。預測期內的成長可歸因於針對特定藥物客製化的預填充式注射器解決方案、可生物分解和永續材料的擴展、聯網和智慧注射器的創新、遠端醫療和遠端醫療應用的增加以及長效注射劑的採用。預測期內的主要趨勢包括預填充式注射器安全性方面的法規合規性、用於精確劑量的智慧連網注射器、可生物分解和環保的注射器材料、針對患者群體客製化的注射器解決方案以及藥物輸送的透明度和可追溯性。
預填充式注射器是一種預先填充了要注射的物質的注射器,可以更容易地將內容物精確地輸送到所需位置。
預填充式注射器主要分為傳統預填充式注射器和安全預填充式注射器。傳統預填充式注射器通常裝有單劑量疫苗,並配有製造商固定的一次性針頭。注射後,注射器即被丟棄。而安全預填充式注射器則裝有單劑量疫苗,供需要定期在家注射的病人自行注射。這些注射器的針頭由玻璃或塑膠等材料製成,且注射器有多種形狀,包括單室預填充式注射器、雙室預填充式注射器和客製化預填充式注射器。這些預填充式注射器用於治療多種疾病,包括糖尿病、類風濕性關節炎、過敏反應、癌症、血栓症和眼科疾病。
2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響,尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制價格上漲,製造商面臨利潤壓力。監管挑戰使情況更加複雜,因為由於關稅而更換供應商通常需要重新認證醫療設備,導致市場進入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司 (The Business Research Company) 最新報告系列之一,提供預充式注射器市場統計數據,包括全球預充式預填充式注射器行業預填充式注射器、各地區市場佔有率、競爭對手的市場佔有率、預填充式注射器預填充式注射器市場的細分市場、市場趨勢和商機,以及在預填充式注射器行業取得成功所需的數據。預填充式注射器市場研究報告對產業現狀和未來趨勢進行了詳細分析,為您提供所需的全方位觀點。
我們預測未來五年該市場將成長14.4%,較先前預測略有下降0.3%。下降主要源自於美國與其他國家之間關稅的影響。美國將直接感受到關稅的影響,包括玻璃桶模和矽膠潤滑系統(以及來自巴西和丹麥的關鍵進口產品)的供應鏈中斷,這可能導致疫苗和生物製藥的交付延遲。此外,互惠關稅以及貿易緊張局勢和限制措施升級對全球經濟和貿易的負面影響也將更廣泛地體現在關稅上。
由於家庭醫療保健的重要性日益增加,預計預填充式注射器市場將在預測期內經歷顯著成長。居家醫療為居家患者提供醫療照護和支持,旨在促進患者康復、管理疾病並提供便利的照護。隨著醫療保健格局的變化,包括對精準給藥、最大限度降低污染風險和提高患者依從性的需求,預計預填充式注射器市場將大幅擴張。這有助於提高患者在家中舒適護理的品質。例如,根據美國居家照護和臨終關懷協會 2023 年 2 月發布的數據,每年約有 1,200 萬美國人接受居家醫療,預計這一數字還將繼續增加。因此,預計家庭醫療保健的快速成長將在預測期內推動市場成長。
癌症治療需求的不斷成長預計將推動預填充式注射器市場的成長。腫瘤治療包括用於診斷、管理和治療癌症的醫療程序和治療方法,例如手術、化療、放射線治療、免疫療法和標靶治療。癌症盛行率的上升、治療方法的進步、早期檢測方法的改進以及人口老化等因素推動了需求的成長,所有這些因素都推動了對有效癌症治療的需求。預填充式注射器在癌症治療中發揮關鍵作用,它能夠提供準確、即用型的化療和生物製藥劑量,簡化給藥流程並提高患者依從性。例如,根據英國慈善機構麥克米倫癌症援助組織的數據,該組織旨在提供實際、情感和經濟支持,以改善癌症患者的生活品質,目前英國癌症患者數量已超過 300 萬,預計到 2025 年將達到 350 萬,到 2030 年將達到 400 萬,到 2040 年將達到 530 萬。因此,對癌症治療的不斷成長的需求預計將推動預填充式注射器市場的成長。
預填充式注射器市場的公司正加大對新一代預填充式注射器的投資,這些注射器具備允許醫護人員追蹤和存取資料的功能。新一代預填充式注射器是指技術先進的注射器,旨在增強藥物輸送、提高病人安全性,並提供連接性和易用性等附加功能。 2022年9月,美國醫療科技公司碧迪公司 (BD) 推出了新一代玻璃預填充式注射器,旨在滿足嚴格的可加工性、外觀、完整性和污染標準。這款名為 BD Effivax 玻璃預灌封注射器的創新注射器是與一家領先的製藥公司合作開發的,旨在滿足不斷變化的疫苗生產需求。
為了擴大其在醫療保健領域的影響力,預填充式注射器市場的領先醫療保健公司正在尋求單劑量預填充式注射器等創新產品的核准。單劑量預填充式注射器是預先裝有注射藥物的一次性注射器,為治療給藥提供了便捷的解決方案。例如,2023年3月,美國食品藥物管理局(FDA)批准了美國製藥公司Nexus Pharmaceuticals Inc.生產的Emerphed(硫酸麻黃鹼注射液)25毫克/5毫升和50毫克/10毫升單劑量預填充式注射器。這是FDA首次核准10毫升(mL)容量的硫酸麻黃鹼注射用核准預填充式注射器。
2022年1月,荷蘭製藥公司北歐製藥 (Nordic Pharma BV) 從賽諾菲 (Sanofi) 手中收購了 ALTIM預填充式注射器的專利。此次收購旨在增強北歐製藥在風濕病領域的產品組合。該公司計劃最佳化該產品的生產流程,並將其重新推向市場,以滿足臨床醫生對該治療方案的持續需求。賽諾菲是一家總部位於法國的製藥和醫療保健公司。
預填充式注射器市場的主要公司包括 Becton, Dickinson and Company、Gerresheimer AG、Schott & Associates Glass Technology Laboratory、West Pharmaceutical Services Inc.、Baxter International、Nipro Corporation、Terumo Corporation、Vetter Pharma International GmbH、Stevanato Group SPA、山東威高集團醫療用高分子材料有限公司、Voltis. AG、Pfizer Inc.、Bristol-Myers Squibb Co.、Hoffmann-La Roche、AbbVie, Inc.、Owen Mumford Holdings, Inc.、 Medtronic, Inc.、Medtronic, Inc.、Abbott Laboratories, Inc.、Fresen Kabi Nabi Ltd.、Medical Protec告訴Medical、ACASI Machinery Inc.、Bespak Holdings Ltd. 和 BioPharma Solutions、Catalent Pharma解決方案、Credence MedSystems Inc.、Hasemeier Inc.、Intas Pharmaceuticals Ltd.、Intelicure Lifesciences、Mycoscience Labs
2024 年,歐洲是預填充式注射器市場最大的地區。預填充式注射器市場分析報告涵蓋的地區包括亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
預填充式注射器市場報告涉及的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國和美國。
預填充式注射器市場包括玻璃預填充式注射器和塑膠預填充式注射器的銷售。該市場的價值是“出廠價”,即商品製造商或生產商銷售給其他營業單位(包括下游製造商、批發商、經銷商和零售商)或直接銷售給最終客戶的價值。該市場中的商品價值還包括商品製造商銷售的任何相關服務。
Pre-filled syringes refer to syringes that come pre-loaded with the substance intended for injection, facilitating the accurate delivery of the contents to the desired location.
The primary types of pre-filled syringes include conventional pre-filled syringes and safety pre-filled syringes. Conventional pre-filled syringes typically contain a single-dose packet of vaccines, with a manufacturer-fixed needle designed for one-time use. After application, the syringe is disposed of. Safety pre-filled syringes, on the other hand, contain a single-dose packet of vaccine intended for self-administration by patients who require regular injections in a home setting. Needles for these syringes are crafted from materials such as glass and plastic, and the syringes come in various forms, including single-chamber pre-filled syringes, dual-chamber pre-filled syringes, and customized pre-filled syringes. These pre-filled syringes find applications in a range of medical conditions such as diabetes, rheumatoid arthritis, anaphylaxis, cancer, thrombosis, ophthalmology, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The pre-filled syringes market research report is one of a series of new reports from The Business Research Company that provides pre-filled syringes market statistics, including pre-filled syringes industry global market size, regional shares, competitors with a pre-filled syringes market share, detailed pre-filled syringes market segments, market trends and opportunities and any further data you may need to thrive in the pre-filled syringes industry. The pre-filled syringe market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pre filled syringes market size has grown rapidly in recent years. It will grow from $8.3 billion in 2024 to $9.39 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to growth in the pharmaceutical and biotechnology industry, expansion of biologics and vaccines, demand for user-friendly and precise drug delivery, increase in home healthcare and self-administration, regulatory standards for drug safety and packaging.
The pre filled syringes market size is expected to see rapid growth in the next few years. It will grow to $16.09 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to customized pre-filled syringe solutions for specific drugs, expansion of biodegradable and sustainable materials, innovation in connected and smart syringes, increased use in telemedicine and telehealth, adoption in long-acting injectable medications. Major trends in the forecast period include regulatory compliance in pre-filled syringe safety, smart and connected syringes for precise dosing, biodegradable and eco-friendly syringe materials, personalized syringe solutions for patient populations, transparency and traceability in drug delivery.
The forecast of 14.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for glass barrel molds and silicone lubrication systems, key imports from Brazil and Denmark, delaying vaccine and biologic drug delivery.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The pre-filled syringe market is anticipated to experience significant growth due to the increasing prominence of home-based healthcare during the forecast period. Home-based healthcare involves providing medical treatment and support to patients in their residences, aiming to facilitate recovery, manage illnesses, and deliver care in the convenience of patients' homes. The pre-filled syringe market is poised for substantial expansion, aligning with the changing healthcare landscape by ensuring precise dosing, minimizing contamination risks, and enhancing patient compliance. This contributes to an elevated quality of care delivered within the comfort of patients' homes. For example, data from the National Association for Home Care and Hospice in February 2023 reveals that around 12 million Americans annually receive home healthcare, with this number expected to continue growing. Hence, the surge in home-based healthcare is anticipated to drive market growth in the forecast period.
The increasing demand for oncology treatment is anticipated to drive growth in the pre-filled syringe market. Oncology treatment encompasses the medical care and therapies employed to diagnose, manage, and treat cancer, including surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies. This heightened demand is fueled by the growing prevalence of cancer, advancements in treatment options, enhanced early detection methods, and a rising aging population, all of which lead to a greater need for effective cancer care. Pre-filled syringes play a crucial role in oncology treatment by providing precise, ready-to-use doses of chemotherapy agents and biologic therapies, simplifying administration, and enhancing patient compliance. For example, according to Macmillan Cancer Support, a UK-based charity dedicated to providing practical, emotional, and financial assistance to those affected by cancer to improve their quality of life, the number of individuals living with cancer in the UK is projected to surpass 3 million currently, reaching 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising demand for oncology treatment will propel the growth of the pre-filled syringe market.
Companies operating in the pre-filled syringes market are increasingly investing in next-generation prefilled syringes, incorporating features that enable healthcare professionals to track and access data. Next-generation pre-filled syringes refer to technologically advanced syringes designed to enhance drug delivery, elevate patient safety, and provide additional features like connectivity and usability. In September 2022, Becton, Dickinson and Company (BD), a US-based medical technology company, introduced a next-generation glass prefillable syringe designed to meet rigorous standards for processability, cosmetics, integrity, and contamination. This innovative syringe, known as BD Effivax Glass Prefillable Syringe, was developed in collaboration with leading pharmaceutical companies to address the evolving requirements of vaccine production.
Leading healthcare companies in the pre-filled syringe market are seeking approval for innovative products, such as single-dose pre-filled syringes, to broaden their presence in the healthcare sector. Single-dose pre-filled syringes, which contain a disposable syringe preloaded with medication liquid for injection, offer a convenient solution for administering treatments. For example, in March 2023, the Food and Drug Administration (FDA) granted approval for Emerphed (ephedrine sulfate injection) in 25 mg/5 mL and 50 mg/10 mL single-dose pre-filled syringes manufactured by Nexus Pharmaceuticals Inc., a US-based pharmaceutical company. This marks the FDA's approval of the first 10-milliliter (mL) pre-filled syringe for ephedrine sulfate injection.
In January 2022, Nordic Pharma B.V., a pharmaceutical company based in the Netherlands, acquired the rights to the ALTIM pre-filled syringe from Sanofi. This acquisition aims to strengthen Nordic Pharma's portfolio in the rheumatology sector. The company intends to optimize the manufacturing process of the product to reintroduce it to the market, addressing the ongoing demand from clinicians for this treatment option. Sanofi S.A. is a pharmaceutical and healthcare company headquartered in France.
Major companies operating in the pre filled syringes market include Becton, Dickinson and Company, Gerresheimer AG, Schott & Associates Glass Technology Laboratory, West Pharmaceutical Services Inc., Baxter International, Nipro Corporation, Terumo Corporation, Vetter Pharma International GmbH, Stevanato Group SPA, Shandong Weigao Group Medical Polymer Company Ltd., Novartis AG, Catalent Inc., Unilife Corporation, Eli Lilly and Company, Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., AbbVie Inc., Owen Mumford Holdings Ltd., AptarGroup Inc., Medtronic Plc, Abbott Laboratories, Fresenius Kabi India Pvt. Ltd., Medical Protective Ltd., Mylan NV, Elcam Medical Inc., YPSOMED Holding AG, Oval Medical Technologies, SHL Medical, ACASI Machinery Inc., Bespak Holdings Ltd., BioPharma Solutions, Catalent Pharma Solutions, Credence MedSystems Inc., Hasemeier Inc., Intas Pharmaceuticals Ltd., Intelicure Lifesciences, Mycoscience Labs
Europe was the largest region in the prefilled syringes market in 2024. The regions covered in the prefilled syringes market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the pre-filled syringes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The pre-filled syringes market consists of sales of glass prefilled syringes and plastic prefilled syringes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pre Filled Syringes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pre filled syringes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pre filled syringes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pre filled syringes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.